Evidence map›Paper›PMID 24816794›Full record

ArticlePloS one2014

Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.

Kihyuck Kwak, Rosie Jiang, Joshua W Wang, Subhashini Jagu, Reinhard Kirnbauer, Richard B S Roden

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Papillomaviruses and Endocytic Trafficking.International journal of molecular sciences · 2018
    Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Kihyuck KwakDepartment of Pathology, The Johns Hopkins University, Baltimore, Maryland, United States of America.
Rosie JiangDepartment of Pathology, The Johns Hopkins University, Baltimore, Maryland, United States of America.
Joshua W WangDepartment of Pathology, The Johns Hopkins University, Baltimore, Maryland, United States of America.
Subhashini JaguDepartment of Pathology, The Johns Hopkins University, Baltimore, Maryland, United States of America.
Reinhard KirnbauerLaboratory of Viral Oncology, Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University Vienna (MUW), Vienna, Austria.
Richard B S RodenDepartment of Pathology, The Johns Hopkins University, Baltimore, Maryland, United States of America; Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland, United States of America; Department of Oncology, The Johns Hopkins University, Baltimore, Maryland, United States of America.
Johns Hopkins University · USMedical University of Vienna · AT

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI Richard Bruce Roden · 2003 to 2026
$53.5M
Mechanisms of Papillomavirus NeutralizationR01CA118790 · NCI · JOHNS HOPKINS UNIVERSITY · PI RODEN, RICHARD BRUCE · 2007 to 2018
$2.9M
A Phase I Study to Evaluate the Safety and Immunogenicity of HPV 16 L2 11-200R01CA133749 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HUH, WARNER KING · 2008 to 2012
$1.4M
NCI NIH HHS CA 118790NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA118790NCI NIH HHS R01 CA133749
6 · The paper itself

Abstract

The licensed human papillomavirus (HPV) vaccines elicit type-restricted immunity but do not target cutaneous HPV types of the beta genus that are associated with non-melanoma skin cancer in immune-compromised patients, and it is unclear if these diverse types share a common mechanism of infection. Residues 11-88 of minor capsid protein L2 contain cross-protective epitopes, and vaccination with concatamers of this region derived from as many as eight alpha HPV (L2 α11-88x8) is being developed as an alternative prophylactic vaccine with potentially broader efficacy. There is also interest in developing broadly protective topical microbicides, such as carrageenan or heparin that block HPV receptor interactions, or small molecule inhibitors of infection. Here we have examined several inhibitors of HPV infection and antisera to L2 α11-88x8 for their breadth of activity against infection by 34 HPV types from within both the alpha and beta families using pseudovirions (PsV) carrying a luciferase reporter as surrogates for native virus. We observed that both heparin and carrageenan prevented infection by mucosatropic HPV types, but surprisingly PsV of several epidermotropic alpha4 and beta HPV types exhibited increased infectivity especially at low inhibitor concentrations. Furin and γ-secretase inhibitors and L2 α11-88x8 antiserum blocked infection by all HPV PsV types tested. These findings suggest that the distinct tropism of mucosal and cutaneous HPV may reflect distinct cell surface receptor interactions, but a common uptake mechanism dependent upon furin and γ-secretase proteolytic activities. Carrageenan, which is being tested as a vaginal microbicide, broadly inhibited infection by the high-risk mucosatropic HPV PsV, but not most skin tropic alpha and beta HPV. Vaccination with an L2 multimer derived exclusively from alpha papillomavirus sequences induced antibodies that broadly neutralized PsV of all 34 HPVs from within both the alpha and beta families, suggesting each displays conserved L2 neutralizing epitopes.

Indexed as

AlphapapillomavirusAmyloid Precursor Protein SecretasesAntigens, ViralBetapapillomavirusBlotting, WesternCapsid ProteinsCarrageenanElectrophoresis, Polyacrylamide GelFurinHeLa CellsHeparinHumansImmune SeraLuciferasesNeutralization TestsPapillomavirus InfectionsAmyloid Precursor Protein SecretasesAntigens, ViralCapsid ProteinsCarrageenanFurinHeparinImmune SeraLuciferasesPapillomavirus Vaccines

Identifiers

PMID24816794
PMCPMC4016295
OpenAlexW2091046596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.